Outlook Therapeutics Inc (OTLK)

[H2R]

Keeping to September 2022 Resubmission

From the August 2022 presentation:

Compelling pivotal data support
U.S. FDA BLA submission targeted
September 2022

Slide 5, https://ir.outlooktherapeutics.com/static-files/8d2c446a-334a-470b-bbbf-9abbf26d2c31

They've kept the same date for the re-submission, since end of May/beginning of June. Their track record in terms of planned and actual steps provides a certain level of confidence.

On the very same slide, they expect (not plan, since FDA timeline) the following:

Launch anticipated Q4 2023,
if approved

Best of luck with your investments!